Patent ID: 9085637
Filing Date: 2015-07-21
Classification: A61K,A61P,C07K

Abstract:
1. A PYY compound, wherein the PYY compound has a maximum of 8 amino acid modifications as compared to hPYY(3-36), wherein the positions corresponding to positions 1-3 of hPYY(1-36) (SEQ ID NO:1) are absent, and wherein the PYY compound comprises (i) tryptophan at the position corresponding to position 30 of hPYY(1-36) (SEQ ID NO:1); (ii) N(alpha)-methyl-L-arginine at a position corresponding to position 35 of hPYY(1-36) (SEQ ID NO:1); (iii) glutamine at a position corresponding to position 18 of hPYY(1-36) (SEQ ID NO:1); (iv) lysine at a position corresponding to position 7 of hPYY(1-36) (SEQ ID NO:1); (v) a modifying group attached to the epsilon amino group of said lysine, wherein said modifying group is defined by A-B-C-, wherein A- is selected from wherein a is 15, c is 13, and wherein * denotes the attachment point to -B-; B- is wherein d is 1; and wherein *** denotes the attachment point to A-, and ** denotes the attachment point to -C-; -C- is wherein g and h is each 1; i is 2; and wherein **** denotes the attachment point to -B-, and ***** denotes the attachment point to the epsilon amino group of the Lysine residue in the position corresponding to position 7 of hPYY(1-36); and (vi) an N-terminal substituent, wherein the N-terminal substituent is selected from 3-methylbutanoyl, 3-methylpentanoyl or hexanoyl; or a pharmaceutically acceptable salt thereof.